ATE464885T1 - Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe - Google Patents

Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe

Info

Publication number
ATE464885T1
ATE464885T1 AT00988234T AT00988234T ATE464885T1 AT E464885 T1 ATE464885 T1 AT E464885T1 AT 00988234 T AT00988234 T AT 00988234T AT 00988234 T AT00988234 T AT 00988234T AT E464885 T1 ATE464885 T1 AT E464885T1
Authority
AT
Austria
Prior art keywords
suspension
delivery system
encapsulated
lipid source
provides
Prior art date
Application number
AT00988234T
Other languages
English (en)
Inventor
Jeff Shear
Al Kershman
Original Assignee
Shear Kershman Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/656,297 external-priority patent/US6541025B1/en
Application filed by Shear Kershman Lab Inc filed Critical Shear Kershman Lab Inc
Application granted granted Critical
Publication of ATE464885T1 publication Critical patent/ATE464885T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00988234T 1999-12-30 2000-12-20 Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe ATE464885T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/476,483 US6340471B1 (en) 1999-12-30 1999-12-30 Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US09/656,297 US6541025B1 (en) 1999-12-30 2000-09-06 Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
PCT/US2000/034776 WO2001049272A2 (en) 1999-12-30 2000-12-20 Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals

Publications (1)

Publication Number Publication Date
ATE464885T1 true ATE464885T1 (de) 2010-05-15

Family

ID=23892036

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00988234T ATE464885T1 (de) 1999-12-30 2000-12-20 Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe

Country Status (3)

Country Link
US (1) US6340471B1 (de)
AT (1) ATE464885T1 (de)
DE (1) DE60044261D1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6541025B1 (en) * 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US9522217B2 (en) * 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US20160287708A9 (en) * 2000-03-15 2016-10-06 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US8088060B2 (en) * 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US7067148B2 (en) * 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
FR2824477B1 (fr) * 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030180356A1 (en) * 2001-10-29 2003-09-25 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
US20040096498A1 (en) * 2002-04-29 2004-05-20 Alvin Kershman Oral pharmaceutical delivery system with improved sustained release
US20050245582A1 (en) * 2002-09-12 2005-11-03 The Hartz Mountain Corporation High concentration topical insecticides containing pyrethroids
US20040202696A1 (en) * 2003-04-14 2004-10-14 Cts Chemical Industries Ltd. Administration form for veterinary use
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
WO2005063156A1 (en) * 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
US20060052676A1 (en) * 2004-09-07 2006-03-09 Yulun Wang Tele-presence system that allows for remote monitoring/observation and review of a patient and their medical records
US20060068020A1 (en) * 2004-09-24 2006-03-30 Cottrell Ian W Encapsulated pharmaceutical agents
JP2009504781A (ja) * 2005-08-17 2009-02-05 アルテアナノ インコーポレイテッド 家畜における高リン血症：治療のための組成物、及び治療方法
US7955632B2 (en) 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US20070128251A1 (en) * 2005-12-07 2007-06-07 Piedmont Pharmaceuticals, Inc. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US7931930B2 (en) * 2006-05-19 2011-04-26 Delavau Llc Delivery of active agents using a chocolate vehicle
US7820221B2 (en) 2006-05-19 2010-10-26 Delavau Llc Delivery of active agents using a chocolate vehicle
CA2718416C (en) * 2008-03-13 2018-01-02 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20100330058A1 (en) * 2009-06-24 2010-12-30 Hero Nutritionals, LLC Chewable drug
AU2010300641B2 (en) * 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
RO125888B1 (ro) * 2010-04-01 2015-07-30 Biofarm S.A. Procedeu de obţinere a unui supliment alimentar cu vitamine şi minerale într-o bază grasă
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2013037650A1 (fr) * 2011-09-15 2013-03-21 Friulchem Spa Compositions pour administration orale aux animaux, leurs procedes d'obtention et leurs utilisations
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
EP2872121B1 (de) 2012-07-12 2018-09-05 SpecGx LLC Missbrauchssichere pharmazeutische zusammensetzungen mit verzögerter freisetzung
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
US10420729B2 (en) 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
CA2901802C (en) 2013-03-15 2021-03-02 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
WO2015145461A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
WO2016004170A1 (en) 2014-07-03 2016-01-07 Mallinckrodt Llc Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
US20160044955A1 (en) 2014-08-13 2016-02-18 R.J. Reynolds Tobacco Company Smokeless tobacco products
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9949499B2 (en) 2015-06-02 2018-04-24 Pet Pill Pal Llc Handheld concealed pill morsel former
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US10532046B2 (en) * 2015-12-03 2020-01-14 Niconovum Usa, Inc. Multi-phase delivery compositions and products incorporating such compositions
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
EP3856160A4 (de) 2018-09-25 2022-07-06 SpecGx LLC Missbrauchssichere kapseldarreichungsformen mit sofortiger freisetzung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
US4749575A (en) 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4581381A (en) 1983-11-14 1986-04-08 Nabisco Brands, Inc. Soft homogeneous antacid tablet
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4797288A (en) * 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
IT1200178B (it) * 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
JP2547995B2 (ja) * 1987-01-26 1996-10-30 昭和電工株式会社 反すう動物用粒剤及びその製造法
GR1001437B (el) 1992-11-05 1993-12-30 Aggelos Kontos Ζαχαροπλαστικό σύστημα χορηγήσεως φαρμακολογικώς δραστικών ουσιών.
GR1002668B (el) 1996-03-15 1997-04-14 N Μεθοδος προσθηκης στειρου αεριου αζωτου και φαρμακολογικως δραστικων ουσιων εις στερεο γιαουρτι.
US6241997B1 (en) 1998-03-16 2001-06-05 Smtm Group. Llc Chewable calcium supplement and method

Also Published As

Publication number Publication date
US6340471B1 (en) 2002-01-22
DE60044261D1 (de) 2010-06-02

Similar Documents

Publication Publication Date Title
ATE464885T1 (de) Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe
Zięba et al. Polymeric carriers for delivery systems in the treatment of chronic periodontal disease
US5876754A (en) Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
Leyva-Gómez et al. Approaches in polymeric nanoparticles for vaginal drug delivery: a review of the state of the art
Panos et al. New drug delivery systems based on chitosan
Binaymotlagh et al. Liposome–hydrogel composites for controlled drug delivery applications
Subramanian Mucoadhesive delivery system: a smart way to improve bioavailability of nutraceuticals
AR022930A2 (es) MICROCAPSULAS, DE TIPO RESERVORIO, QUE CONTIENEN POR LO MENOS UN PRINCIPIO ACTIVO MEDICAMENTOSO Y/O NUTRITIVO (PA) CON EXCLUSION DEL ACIDO ACETILSALICILICO (ASA), DESTINADAS A LA ADMINISTRACION POR VIA ORAL, SU UTILIZACIoN Y FORMA FARMACEUTICA QUE COMPRENDE A DICHAS MICROCAPSULAS.
NO20010264L (no) Bionedbrytbare preparater for kontrollert frigivelse av innkapslede stoffer
WO2001049272A3 (en) Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
DE69812936T2 (de) Arzneimittel in form parenenteral verabreichbarer lipidmikropartikel
ATE264671T1 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
NO934315D0 (no) Farmas!ytisk b{rer
RU94041221A (ru) Способ получения пористых средств доставки лекарственных препаратов
SE8903503D0 (sv) Kombination av pseudoplastisk gel och ett partikelformat, kristallint eller frystorkat laekemedel foer parenteral administrering och ett saett att bereda en saadan kombination
DE3680866D1 (de) Herstellungsverfahren fuer arzneimittel mit verzoegerter wirkstoffabgabe.
AR006087A1 (es) Forma de dosificación para la administración de clorhidrato de verapamil a una velocidad de liberación uniforme.
ATE290854T1 (de) Carbamazepinformulierung mit verzögerter freigabe
BR0109802A (pt) Preparações farmacêuticas e sua fabricação
Penteado et al. Chitosan-coated poly (є-caprolactone) nanocapsules for mucoadhesive applications of perillyl alcohol
JPS5989634A (ja) 遅れて作用物質を放出する固形のプレスされた薬物配合物及びその製造方法
CN1654510A (zh) 一种纳米微凝胶、其制备方法及应用
BR9806303A (pt) Sistema de distrituição de droga termoformado, e, unidade de dosagem
RU2256440C2 (ru) Фармацевтический препарат
Gholse et al. Microencapsulation for the therapeutic delivery of Proteins and other drugs: Update and future challenges

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties